GlassScriptPhysician profile
Cindy Kweon
NPI 1386244887
$2,180.21
in general payments reported to CMS, 2019-2025
19 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $556 · 2022: $609 · 2023: $533 · 2024: $247 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.52 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $315.34 | 2021-2023 | Cequa |
| Bausch & Lomb Americas INC. | $260.49 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $231.43 | 2021 | |
| Alcon Vision LLC | $134.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.67 | 2025 | Reblozyl |
| Aerie Pharmaceuticals, INC. | $107.99 | 2021 | |
| Oyster Point Pharma, INC. | $77.68 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $77.13 | 2025 | Vevye |
| Amgen INC. | $38.23 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $30.55 | 2022 | |
| Sight Sciences, INC. | $27.47 | 2022 | |
| Kala Pharmaceuticals, INC. | $26.27 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.83 | 2021 | |
| Abb Con-Cise Optical Group LLC | $22.77 | 2024 | Contact Lens, Spectacle Lenses |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $19.33 | 2022 | |
| Thea Pharma INC. | $19.14 | 2023 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $18.37 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Kweon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.